Solventum Corporation SOLV SPX
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Strong return on equity of 34.8%.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SOLV Solventum Corporation SPX | 74.95 | 9.17 | $12.98B | - | 18.46% | 34.79% | 0.79% | 5.03% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.01B | 2.08B | 2.07B | 2.02B | 2.08B | - | 2.07B | 2.16B | 2.10B | 2.00B | 2.01B |
| Cost of Revenue | - | - | - | - | - | - | 956.00M | 986.00M | 961.00M | 971.00M | 911.00M |
| Gross Profit | 1.14B | 1.19B | 1.21B | 1.17B | 1.14B | - | 1.11B | 1.18B | 1.14B | 1.03B | 1.09B |
| Operating Expenses | - | - | - | - | - | - | 962.00M | 961.00M | 963.00M | 934.00M | 1.02B |
| Operating Income | 365.00M | 417.00M | 504.00M | 381.00M | 244.00M | - | 152.00M | 214.00M | 172.00M | 93.00M | 79.00M |
| EBITDA | - | - | - | - | - | - | 271.00M | 328.00M | 1.72B | 226.00M | 213.00M |
| Interest Expense | - | - | - | - | - | - | 104.00M | 103.00M | 89.00M | 51.00M | 62.00M |
| Pretax Income | - | - | - | - | - | - | 38.00M | 103.00M | 1.51B | 58.00M | 16.00M |
| Tax Provision | - | - | - | - | - | - | -99.00M | 13.00M | 248.00M | -5.00M | 3.00M |
| Net Income | 293.00M | 321.00M | 460.00M | 237.00M | 89.00M | - | 137.00M | 90.00M | 1.27B | 63.00M | 13.00M |
| Diluted EPS | 1.70 | 1.86 | 2.66 | 1.37 | 0.51 | - | 0.78 | 0.51 | 7.22 | 0.36 | 0.07 |
| R&D Expense | 195.00M | 193.00M | 180.00M | 195.00M | 192.00M | 189.00M | 193.00M | 189.00M | 183.00M | - | 189.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 8.13B | 8.20B | 8.25B | 8.32B |
| Cost of Revenue | - | 3.44B | 3.50B | 3.66B | 3.87B |
| Gross Profit | - | 4.70B | 4.69B | 4.59B | 4.45B |
| Operating Expenses | - | 3.00B | 3.06B | 3.56B | 3.82B |
| Operating Income | - | 1.69B | 1.64B | 1.04B | 632.00M |
| EBITDA | - | 2.27B | 2.23B | 1.53B | 2.55B |
| Interest Expense | - | 0 | 0 | 367.00M | 347.00M |
| Pretax Income | - | 1.69B | 1.67B | 605.00M | 1.71B |
| Tax Provision | - | 349.00M | 321.00M | 127.00M | 157.00M |
| Net Income | - | 1.34B | 1.35B | 479.00M | 1.56B |
| Diluted EPS | - | 7.78 | 7.79 | 2.76 | 8.88 |
| R&D Expense | - | 767.00M | 758.00M | 775.00M | 739.00M |
Compounded Sales Growth
| 5 Years: | 0.79% |
| 1 Year: | -3.00% |
Compounded Profit Growth
| 5 Years: | 5.03% |
| 1 Year: | -91.00% |
Stock Price Performance
| 1 Year: | +2.54% |
| 6 Months: | -12.62% |
| 3 Months: | +1.01% |
| 1 Month: | +12.72% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 13.59B | 13.94B | 14.46B | 14.29B |
| Current Assets | - | 2.23B | 2.52B | 3.25B | 3.86B |
| Cash & Equivalents | - | 61.00M | 194.00M | 762.00M | 878.00M |
| Inventory | - | 873.00M | 857.00M | 965.00M | 1.07B |
| Receivables | - | 1.17B | 1.31B | 1.04B | 1.03B |
| Total Liabilities | - | 1.85B | 2.28B | 11.50B | 9.24B |
| Current Liabilities | - | 1.31B | 1.73B | 2.70B | 3.14B |
| Long Term Debt | - | - | 8.30B | 7.81B | 5.04B |
| Total Debt | - | - | 8.30B | 8.01B | 5.04B |
| Total Equity | - | 11.74B | 11.67B | 2.96B | 5.05B |
| Shares Outstanding | - | 172.71M | 172.71M | 172.79M | 173.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 1.68B | 1.92B | 1.19B | 369.00M |
| Investing Cash Flow | - | -253.00M | -230.00M | -380.00M | 2.80B |
| Financing Cash Flow | - | -1.46B | -1.55B | -240.00M | -3.06B |
| Capital Expenditure | - | -251.00M | -290.00M | -380.00M | -379.00M |
| Free Cash Flow | - | 1.43B | 1.62B | 805.00M | -10.00M |
| Net Change in Cash | - | -34.00M | 133.00M | 565.00M | 109.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 57.7% | 57.3% | 55.6% | 53.5% |
| Operating Margin % | - | 20.8% | 20.0% | 12.6% | 7.6% |
| Net Margin % | - | 16.5% | 16.4% | 5.8% | 18.7% |
| ROE % | - | 11.4% | 11.5% | 16.2% | 30.8% |
| ROCE % | - | 13.8% | 13.4% | 8.8% | 5.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Independent Franchise Partners, LLP | 9.09% | 15.73M | $1.18B |
| 2 | Blackrock Inc. | 6.05% | 10.48M | $785.40M |
| 3 | Vanguard Capital Management LLC | 5.54% | 9.60M | $719.67M |
| 4 | Trian Fund Management, LP | 4.76% | 8.24M | $617.34M |
| 5 | State Street Corporation | 3.70% | 6.41M | $480.24M |
| 6 | Vanguard Portfolio Management LLC | 3.69% | 6.39M | $478.96M |
| 7 | Davis Selected Advisers | 3.66% | 6.33M | $474.46M |
| 8 | Geode Capital Management, LLC | 2.74% | 4.75M | $356.18M |
| 9 | Boston Partners | 2.26% | 3.91M | $293.36M |
| 10 | Invesco Ltd. | 2.19% | 3.79M | $284.05M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SOLV
The Download: climate tech goes public and the AI Hype Index returns
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Climate tech companies are going public. What’s ne…
Climate tech companies are going public. What’s next?
This year, there’s been a wave of notable energy companies going public via IPO in the US. The solar and battery company Solv Energy went public in February, to the tune of $6 billion. X-energy, which…